Results 21 to 30 of about 34,901 (267)

MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates

Journal of Global Antimicrobial Resistance, 2020
Objectives: The aim of this study was to correlate the results of a modified susceptibility testing method with outcomes of ceftazidime/avibactam (CAZ/AVI) therapy. Methods: Two bloodstream K.
Andrei Zidaru, Brianna M. Eales, Weiqun Wang, Paul R. Merlau, Todd M. Lasco, Amelia K. Sofjan, Vincent H. Tam   +6 more
doaj   +1 more source

Discovery of beta-lactamase CMY-10 inhibitors for combination therapy against multi-drug resistant Enterobacteriaceae.

PLoS ONE, 2021
β-lactam antibiotics are the most widely used antimicrobial agents since the discovery of benzylpenicillin in the 1920s. Unfortunately, these life-saving antibiotics are vulnerable to inactivation by continuously evolving β-lactamase enzymes that are ...
Nousheen Parvaiz, Faisal Ahmad, Wenbo Yu, Alexander D MacKerell, Syed Sikander Azam   +4 more
doaj   +1 more source

Synthesis and evaluation of 1, 2, 3-triazole benzoate derivatives for inhibition of serine β-lactamases in extensively drug resistant pathogenic E. coli strains

European Journal of Medicinal Chemistry Reports, 2023
The β-lactamase enzyme is a leading cause of drug resistance developed by bacteria. The combination of β-lactam (BL) antibiotics with an appropriate β-lactamase inhibitor (BLI) is a fundamental approach used to circumvent the problem of β-lactamase ...
Harshal S. Oman, Archana A. Kharat, Pramod S. Phatak, Kishan P. Haval, Jeetendra A. Kulkarni, Ganesh S. Kakde, Kiran R. Kharat, Dilip G. Kadam, Arun S. Kharat   +8 more
doaj   +1 more source

Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying <i>bla</i>_OXA-48. [PDF]

Microbiol Spectr
Mojica MF, Zeiser ET, Becka SA, Six DA, Moeck G, Bonomo RA, Papp-Wallace KM.   +6 more
europepmc   +2 more sources

Fluoroquinolones versus β-Lactam/β-Lactamase Inhibitors in Outpatients with Chronic Obstructive Pulmonary Disease and Pneumonia: A Nationwide Population-Based Study. [PDF]

PLoS ONE, 2015
Studies on the association between antibiotic treatment and outcomes in outpatients with chronic obstructive pulmonary disease (COPD) and pneumonia are scarce.
Kuan-Yin Lin, Chi-Chuan Wang, Chia-Hui Lin, Wang-Huei Sheng, Shan-Chwen Chang   +4 more
doaj   +1 more source

The reaction mechanism of metallo-beta-lactamases is tuned by the conformation of an active site mobile loop [PDF]

, 2018
Carbapenems are "last resort" β-lactam antibiotics used to treat serious and life-threatening health care-associated infections caused by multidrug-resistant Gram-negative bacteria.
Alzari, Pedro M., Bethel, Christopher R., Bonomo, Robert A., Giannini, Estefanía, Klinke, Sebastian, Llarrull, Leticia Irene, Mojica, María F., Otero, Lisandro Horacio, Palacios, Antonela Rocio, Taracila, Magdalena A., Vila, Alejandro Jose   +10 more
core   +1 more source

Inhibiting the β-Lactamase of Mycobacterium tuberculosis (Mtb) with Novel Boronic Acid Transition-State Inhibitors (BATSIs) [PDF]

, 2015
BlaC, the single chromosomally-encoded β-lactamase of Mycobacterium tuberculosis, has been identified as a promising target for novel therapies that rely upon β-lactamase inhibition.
Bethel, Christopher R., Blanchard, John S., Bonomo, Robert A., CASELLI, Emilia, Hazra, Saugata, Kurz, Sebastian G., PRATI, Fabio, ROMAGNOLI, Chiara   +7 more
core   +1 more source

Amphiphilic nebramine analogs synergize with β-lactam/β-lactamase inhibitor combinations, including cefepime-taniborbactam and meropenem-xeruborbactam against metallo-β-lactamase-carrying <i>Pseudomonas aeruginosa</i>. [PDF]

RSC Med Chem
Lozeau C, Ramirez D, Ramirez D, Kumar G, Arora R, Zhanel G, Arthur G, Schweizer F.   +7 more
europepmc   +3 more sources

The Distribution of ESBL-Producing Enterobacteriaceae: Leicestershire UK Compared to Worldwide [PDF]

, 2019
open access ...
Reid, R., Samarasinghe, S., Varnakulasingam, Atheena   +2 more
core   +1 more source

Activity of OP0595-β-lactam combination against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactama [PDF]

, 2015
Background: OP0595 is a diazabicyclooctane that (i) acts as a PBP2-ctive antibacterial, (ii) inhibits Class A and C β-lactamases and (iii), like mecillinam, gives β-lactamase-independent potentiation of β-lactams targeting other PBPs.
Livermore, David M., Mushtaq, Shazad, Warner, Marina, Woodford, Neil   +3 more
core   +1 more source